International Workshop on Lung Health

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, Patient, HKEX, Research, PD-L1, Hepatitis B virus, Trial of the century, Harvard Medical School, AIDS, National Institutes of Health, Lim, Johns Hopkins University, Arbutus, Prevalence, Jacob Aligo, Safety, PD-1, University of Milan, CHB, University of Hong Kong, Virus, Phase, Immunotherapy, Risk, HIV/AIDS research, International Workshop on Lung Health, Bangladesh Technical Education Board, GSK, University, Roche, HBsAg, VIR, University of Oxford, Toronto Centre, Liver disease, HBV, Hook effect, Village Vanguard Live Sessions 3, Vaccine, Pharmaceutical industry, Northwestern University, Immunocore

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Research, Medical Supplies, General Health, Health, Infectious Diseases, Other Health, The Union, Vaccine, TB, Gram-positive bacteria, International Workshop on Lung Health, Conference, Union, Lung, Public, Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Longhorn, Peptidoglycan

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.
  • The ePoster will be presented as a part of TBScience 2023, a dedicated event focused on basic and translational tuberculosis (TB) research.
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines Mycobacterium tuberculosis heat shock protein and Peptidoglycan to generate broad reactive antibodies.
  • ePoster Session Title: TB within the Global AMR fight: preventing drug resistance
    Over the last 53 years, the Union World Conference on Lung Health has presented the latest scientific research in all aspects of lung health, including implementation of evidence-based health policies and decisions.

Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023

Retrieved on: 
Tuesday, October 31, 2023
MEDICA, FDA, Research, Sale, Exhibition, CSO, AMP, Journal of NIH Research, International Workshop on Lung Health, Conference, PCR, Health, SALT, Union, AdvaMed, Pharmaceutical industry, Medical device, Booth

Utah Life Sciences Summit in Salt Lake City; Nov. 9, 2023: This event will feature leading experts in the life sciences industry gathered from around the country.

Key Points: 
  • Utah Life Sciences Summit in Salt Lake City; Nov. 9, 2023: This event will feature leading experts in the life sciences industry gathered from around the country.
  • "A study by Advamed ranked Utah as #8 in the country for production of medical devices and #9 for total employees in the medical device space."
  • AMP in Salt Lake City; Nov. 14-18, 2023: The Association for Molecular Pathology (AMP) is a leading organization in the field of molecular diagnostics.
  • Co-Dx CEO Dwight Egan will also be giving an innovation spotlight presentation on Stage #1 at 9:30-10:30 AM MT on November 17, 2023.

Drs. Susan O'Brien and Catherine Wu Presented the Binet-Rai Medal at 20th International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Woman, Physician, International Workshop on Lung Health, Abstract, Research, Biology, Epidemiology, Proteomics, Metabolism, Health, Medal, CLL, Genomics, BTK, Patient, Chronic lymphocytic leukemia, Medical device, DRS, MD

BOSTON, Oct. 10, 2023 /PRNewswire/ -- During this past weekend's 20th biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) , Susan M. O'Brien, MD, and Catherine J. Wu, MD, were awarded the Binet-Rai Medal.

Key Points: 
  • BOSTON, Oct. 10, 2023 /PRNewswire/ -- During this past weekend's 20th biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) , Susan M. O'Brien, MD, and Catherine J. Wu, MD, were awarded the Binet-Rai Medal.
  • iwCLL presents the Binet-Rai Medal to individuals who shape scientific understanding of CLL through important research.
  • Dr. Catherine Wu is an internationally recognized expert in the biology and treatment of lymphoid malignancies, with a primary focus on CLL.
  • Dr. O'Brien stated: "I'm speechless and delighted, not just that I was presented this award, but that Dr. Wu was as well.

The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

Retrieved on: 
Tuesday, October 10, 2023
Diagnosis, Partnership, International Workshop on Lung Health, BeiGene, Death, Patient, Leukemia, Access, Health equity, Physician, Chronic lymphocytic leukemia, Hospital, Management, Nursing, Humanitarianism, Developing country, CLL

SEATTLE, Oct. 10, 2023 /PRNewswire/ -- The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, and the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), an international, nonprofit association committed to advancing the management and outcome of patients with CLL worldwide, today announced a collaboration to improve the care of people living with CLL in low- and middle-income countries (LMICs).

Key Points: 
  • "We are thrilled to partner with iwCLL to improve outcomes in CLL in LMICs," said Pat Garcia-Gonzalez, CEO of Max.
  • "We are thrilled to partner with iwCLL to improve outcomes in CLL in LMICs," said Pat Garcia-Gonzalez, CEO of Max.
  • CLL is the most common leukemia in adults, accounting for about one third of new cases of leukemia worldwidei.
  • Globally, there are around 40,000 deaths due to CLL per year2.

Lung Health Foundation Welcomes Rachel Jacobs as New Vice President of Partnerships and Development

Retrieved on: 
Thursday, October 5, 2023
Partnership, Infection, Child, Smoking, Lung cancer, Asthma, COPD, Question, Respiratory disease, Prevalence, CAMH, Organization, BC Children's Hospital Foundation, Centre for Addiction and Mental Health, Mental health, CCHF, U8 Global Student Partnership for Development, Addiction, PSAS, International Workshop on Lung Health, Attention, Research, Pharmaceutical industry, Nursing, Management

TORONTO, Oct. 5, 2023 /CNW/ - The Lung Health Foundation is pleased to announce the appointment of Rachel Jacobs as the new Vice President of Partnerships and Development.

Key Points: 
  • TORONTO, Oct. 5, 2023 /CNW/ - The Lung Health Foundation is pleased to announce the appointment of Rachel Jacobs as the new Vice President of Partnerships and Development.
  • Prior to joining the Lung Health Foundation, Rachel held senior roles in several prominent organizations.
  • On her appointment, Rachel Jacobs remarked, "It's an honour to be part of the Lung Health Foundation at such a critical and transformative time.
  • The Lung Health Foundation aims to change the narrative surrounding lung disease, ensuring its prevalence and significance remain top of mind.

Largest International Assembly on Chronic Lymphocytic Leukemia (CLL) Raises Curtain on 20th Biennial Meeting in Boston, Massachusetts

Retrieved on: 
Tuesday, October 3, 2023
CLL, International Workshop on Lung Health, Abstract, Partnership, Lymphoproliferative disorders, Epidemiology, Court of general sessions, Research, Genomics, Doctor of Philosophy, BTK, Proteomics, Hynes Convention Center, Harvard Medical School, Medicine, Metabolism, MD, Patient, Physician, Hematology, XX, Diagnosis, Chronic lymphocytic leukemia, Leukemia, Health, Social media, Disease, Dana–Farber Cancer Institute, Medical device, Veterinary medicine

BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts. Founded in 1979, iwCLL is the world's leading member-driven organization dedicated to the field of CLL and related lymphoproliferative disorders, bringing together leaders from scientific research, clinical medicine, and the pharmaceutical and biotechnology industries.

Key Points: 
  • BOSTON, Oct. 3, 2023 /PRNewswire/ -- On Friday, October 6, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) will commence its 20th biennial meeting (XX iwCLL) at the Hynes Convention Center in Boston, Massachusetts.
  • The International Workshop on Chronic Lymphocytic Leukemia hosts its 20th biennial meeting in Boston on Oct. 6-9, 2023.
  • "Recent data from both the laboratory and clinic have reignited the CLL community's enthusiasm and dedication toward finding a cure.
  • The 4-day event will begin on Friday with a Young Investigator Meeting, applicable for individuals early in their hematology careers.

GSK announces largest private financial contribution to CIHR's Team Grants initiative addressing threats to Canadian lung health

Retrieved on: 
Tuesday, September 26, 2023
Heart, GSK, British Thoracic Society, Canadian Thoracic Society, Atmosphere, Gas, Wildfire, Overalls, Water quality, International Workshop on Lung Health, COVID-19, Radon, Woman, Public, CIHR, Research, Brain, Inhalation, Lung cancer in Australia, History, Lung, Indigenous peoples, Death, Climate change, Patient, Risk, Canadian Institutes of Health Research, Viral, Health, Smoking, Air pollution, Virus, Herbal cigarette, Pharmaceutical industry, MISSISSAUGA

The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative.

Key Points: 
  • The funds will be managed and administered by the Canadian Institutes of Health Research (CIHR) through the Team Grants in Lung Health initiative.
  • GSK's contribution is the largest private financial contribution to this research initiative to date.
  • GSK is investing $2 million in research to address ongoing, new, and emerging threats to lung health in Canada.
  • Considering these and other significant threats to lung health, such as lung cancers, the effects of vaping on health, viral infections such as COVID-19, and the impacts of climate change, there is an urgent need for strategic investment in lung health research.1
    "The CIHR's Team Grants in Lung Health is the single largest investment in lung health research in the history of CIHR.

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Retrieved on: 
Wednesday, August 16, 2023
Lymphoma, International Workshop on Lung Health, Waldenström macroglobulinemia, US Foods, University, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, University of Washington, Clinical trial, Immunoglobulin M, Bone marrow, NHL, PET-CT, Immunotherapy, Associate, Translation, Regenerative medicine, WM, Patient, Cancer, CR, Orphan, Diagnosis, Trial of the century, Hairy cell leukemia, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, DSM-IV codes, Food, Safety, Disease, Grade 2, Medical imaging, Vaccine, Pharmaceutical industry

WORCESTER, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced the first data from the indolent lymphoma cohort of the Company’s ongoing multicenter Phase 1/2 clinical trial evaluating MB-106, a first-in-class CD20-targeted, autologous CAR-T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”), demonstrating clinical responses as well as safety and efficacy consistent with the ongoing Phase 1/2 clinical trial taking place at Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • The multicenter data also show persistence of CAR-T cells at 6+ months and favorable safety data with only Grade 1 cytokine release syndrome (“CRS”) reported to date.
  • Additionally, the data from the ongoing clinical trial at Fred Hutch continue to demonstrate a high rate of complete and durable responses.”
    Dr. Shadman also presented data from the ongoing Fred Hutch Phase 1/2 clinical trial, specific to two B-NHL cohorts, follicular lymphoma (“FL”) and WM.
  • Furthermore, Mustang anticipates requesting regenerative medicine advanced therapy (RMAT) designation for WM from the FDA in 2024.
  • Finally, data from the Fred Hutch clinical trial also support the potential of MB-106 to be administered as outpatient therapy and provide a best-in-class immunotherapy option for patients treated previously with CD19-directed CAR-T cell therapy.

Renaming obesity won't fix weight stigma overnight. Here's what we really need to do

Retrieved on: 
Sunday, July 30, 2023
People, Pregnancy, Obesity, Education, Classification, Facial muscles, Public, Workplace, Homosexuality, International Workshop on Lung Health, Nonsense, Weight gain, Terminology, Name, Stigma, Social stigma of obesity, Non-alcoholic fatty liver disease, Adipose tissue, BMI, Health, Environment, Human, Lizzo, Body size and species richness, Disease, Pig, Consumer electronics, Convenience food, Dietary supplement, Life insurance, Medical imaging, Soft drink, Meat, Vaccine

Some researchers think the term “obesity” itself is part of the problem, and are calling for a name change to reduce stigma.

Key Points: 
  • Some researchers think the term “obesity” itself is part of the problem, and are calling for a name change to reduce stigma.
  • We study the stigma that surrounds obesity – around the time of pregnancy, among health professionals and health students, and in public health more widely.
  • Here’s what’s really needed to reduce weight stigma.

Weight stigma is common

    • Up to 42% of adults living in larger bodies experience weight stigma.
    • Weight stigma is associated with harms including increased cortisol levels (the main stress hormone in the body), negative body image, increased weight gain, and poor mental health.
    • Weight stigma may even pose a greater threat to someone’s health than increasing body size.

Should we rename obesity?

    • Calls to remove or rename health conditions or identifications to reduce stigma are not new.
    • Following many years of protests and activism, the term and condition were removed from the globally recognised classification of mental health disorders.
    • Perhaps it is finally time to follow suit and rename obesity.

A new name needs to go beyond BMI

    • First, most people use the term for people with a body-mass index (BMI) of 30kg/m² or above.
    • Most, if not all, public health organisations also use BMI to categorise obesity and make assumptions about health.
    • However, BMI alone is not enough to accurately summarise someone’s health.

Is obesity a disease anyway?

    • Yet there is still no universal consensus on whether obesity is a disease.
    • By this definition, obesity may not be classified as a disease until after harm from the additional weight occurs.
    • Renaming obesity may improve public understanding that while obesity is often associated with an increase in BMI, the increased BMI itself is not the disease.

Workshopping alternatives


    Before deciding to rename obesity, we need discussions between obesity and stigma experts, health-care professionals, members of the public, and crucially, people living with obesity. Such discussions can ensure robust evidence informs any future decisions, and proposed new terms are not also stigmatising.

    Read more:
    Today's disease names are less catchy, but also less likely to cause stigma

What else can we do?

    • Our constant exposure to the socially-defined and acceptable idealisation of smaller bodies (the “thin ideal”) and the pervasiveness of weight stigma means this stigma is deeply ingrained at a societal level.
    • Blake Lawrence is a member of The Obesity Society and The Obesity Collective.